<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fluticasone Propionate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00588</strong>&#160; (APRD00065)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase&#174;. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista&#8482;. Dymista&#8482; is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00588/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00588/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00588.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00588.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00588.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00588.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00588.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00588">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Fluticason</td><td>German</td><td>INN</td></tr><tr><td>Fluticasona</td><td>Spanish</td><td>INN</td></tr><tr><td>Fluticasone</td><td>French</td><td>INN</td></tr><tr><td>Fluticasonum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fluticasone Propionate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001035/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001035/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001035">DBSALT001035</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cutivate</td><td>GlaxoSmithKline</td></tr><tr><td>Ezicas</td><td>Intas</td></tr><tr><td>Flixonase</td><td>GlaxoSmithKline</td></tr><tr><td>Flixotide</td><td>GlaxoSmithKline</td></tr><tr><td>Flonase</td><td>GlaxoSmithKline</td></tr><tr><td>Flovent</td><td>GlaxoSmithKline</td></tr><tr><td>Flovent HFA</td><td>GlaxoSmithKline</td></tr><tr><td>FLOVENTHFA</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Flunase</td><td>GlaxoSmithKline</td></tr><tr><td>Nasofan</td><td>Teva</td></tr><tr><td>Pirinase</td><td>GlaxoSmithKline</td></tr><tr><td>Seretide</td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>ADVAIR</td><td>Fluticasone Propionate + Salmeterol</td></tr><tr><td>ADVAIRDISKUS</td><td>Fluticasone Propionate + Salmeterol</td></tr><tr><td>Dymista</td><td>Azelastine hydrochloride and Fluticasone propionate</td></tr><tr><td>Flixotide</td><td>Fluticasone and Salmeterol</td></tr><tr><td>Flixovent</td><td>Fluticasone and Salmeterol</td></tr><tr><td>Flosal Diskus</td><td>Fluticasone and Salmeterol</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>80474-14-2</td></tr><tr><th>Weight</th><td>Average: 500.571<br>Monoisotopic: 500.184429407</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>31</sub>F<sub>3</sub>O<sub>5</sub>S</td></tr><tr><th>InChI Key</th><td>WMWTYOKRWGGJOA-CENSZEJFSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0&#178;,&#8311;.0&#185;&#185;,&#185;&#8309;]heptadeca-3,6-dien-14-yl propanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Steroid Esters</td></tr><tr><th>Direct parent</th><td>Steroid Esters</td></tr><tr><th>Alternative parents</th><td>Androgens and Derivatives; Halogenated Steroids; Ketosteroids; Hydroxysteroids; Iridoids and Derivatives; Cyclohexanols; Thioesters; Carboxylic Acid Esters; Ketones; Fluorohydrins; Cyclic Alcohols and Derivatives; Thiocarboxylic Acid Esters; Ethers; Polyamines; Enolates; Organofluorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>3-keto-steroid; 11-hydroxy-steroid; 9-halo-steroid; 6-halo-steroid; 11-noriridane monoterpene; monoterpene; cyclohexanol; cyclic alcohol; carboxylic-thioester; carboxylic acid ester; thiocarboxylic acid ester; halohydrin; fluorohydrin; ketone; secondary alcohol; enolate; carboxylic acid derivative; polyamine; thiocarboxylic acid derivative; ether; organohalogen; alcohol; organofluoride; carbonyl group; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the steroid esters. These are compounds containing a steroid moeity which bears a carboxylic acid ester group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma.</td></tr><tr><th>Pharmacodynamics</th><td>Fluticasone is an extremely potent vasoconstrictor and anti-inflammatory agent. Its effectiveness in inhaled forms is due to its direct local effect.</td></tr><tr><th>Mechanism of action</th><td>Binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.</td></tr><tr><th>Absorption</th><td>The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier.
Bioavailability, intranasal = </td></tr><tr><th>Volume of distribution</th><td><p>IV administration = 4.2 L/kg</p></td></tr><tr><th>Protein binding</th><td>91%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Fluticasone Propionate</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00450">fluticasone 17beta-carboxylic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/459">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Less than 5% of the oral dose was excreted in the urine as metabolites. The rest of the dose is excreted in the feces and parent drug and metabolites. </td></tr><tr><th>Half life</th><td>Terminal elimination half-life = 7.8 hours </td></tr><tr><th>Clearance</th><td><p>The total blood clearance of fluticasone propionate is high (average, 1,093 mL/min), with renal clearance accounting for less than 0.02% of the total.</p></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9964</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9701</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5417</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7099</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7192</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8636</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8689</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.868</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7407</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8988</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8682</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.798
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8901
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3753 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.99
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6125
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Glaxosmithkline</li>
<li>Glaxo group ltd dba glaxosmithkline</li>
<li>Altana inc</li>
<li>G and w laboratories inc</li>
<li>Kv pharmaceutical co</li>
<li>Perrigo new york inc</li>
<li>Tolmar inc</li>
<li>Nycomed us inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Apotex inc richmond hill</li>
<li>Hi tech pharmacal co inc</li>
<li>Roxane laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.fougera.com">E. Fougera and Co.</a></li>
<li><a href="http://www.gwlabs.com">G &amp; W Labs</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.hitechpharm.com">Hi Tech Pharmacal Co. Inc.</a></li>
<li><a href="http://www.letcomedical.com">Letco Medical Inc.</a></li>
<li><a href="http://www.nycomed.com">Nycomed Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>Penn Labs</li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li><a href="http://www.pharmaderm.com">Pharmaderm</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Professional Co.</li>
<li>Promex Medical Inc.</li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tolmar.com">Tolmar Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Aerosol, metered</td><td>Respiratory (inhalation)</td><td></td></tr><tr><td>Cream</td><td>Topical</td><td></td></tr><tr><td>Powder</td><td>Respiratory (inhalation)</td><td></td></tr><tr><td>Spray, metered</td><td>Nasal</td><td></td></tr><tr><td>Spray, metered</td><td>Nasal</td><td>DYMISTA : 0.137MCG /SPRAY; 0.05MCG/SPRAY (AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE) </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended. </td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Concurrent use with crizotinib may prolong QTc interval. Consider alternative therapy. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Fluticasone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fluticasone if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Fluticasone propionate. Concomitant therapy should be avoided if possible.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fluticasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluticasone if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>